Strides Pharma Science (BOM:532531) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Strides Pharma Science LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Strides Pharma Science's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Strides Pharma Science's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Strides Pharma Science LT-Debt-to-Total-Asset Historical Data

The historical data trend for Strides Pharma Science's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strides Pharma Science LT-Debt-to-Total-Asset Chart

Strides Pharma Science Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.14

0.16

0.15

0.20

0.13

Strides Pharma Science Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.13	-	0.11	-

Strides Pharma Science LT-Debt-to-Total-Asset Calculation

Strides Pharma Science's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	7431.34	/	58397.55
	=	0.13

Strides Pharma Science's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0	/	0
	=

Strides Pharma Science (BOM:532531) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Strides Pharma Science LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Strides Pharma Science's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Strides Pharma Science Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Strides Pharma Science Ltd (BOM:532531) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

STAR:India

Address

Strides House, Bannerghatta Road, Bilekahalli, Bengaluru, KA, IND, 560 076

Website

https://www.strides.com

Strides Pharma Science Ltd is a specialty and generic drug manufacturer. The company focuses on developing niche and complex pharmaceutical products across therapeutic segments for regulated and emerging markets. Strides' emerging-market plan focuses on branded generics for the treatment of chronic therapies. The company considers merger and acquisition investment as a potential component of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. The company's reportable segment are; Pharmaceutical & Bio-pharmaceutical.

Strides Pharma Science Headlines

No Headlines